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Background: Previously, we performed analysis of gene expression in 46 axillary lymph node negative tumors and
identified molecular gene signatures that resulted in different clinical outcomes. The aim of this study was to
determine the correlation of γ-glutamyl hydrolase (GGH), fatty acid amide hydrolase (FAAH), Pirin (PIR) and TAF5-like
RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa (TAF5L), selected from identified
gene signatures, with clinical outcomes as well as classical clinicopathological characteristics in primary invasive
breast cancer patients.
Methods: The protein levels of GGH, FAAH, PIR and TAF5L were assessed by immunohistochemistry (IHC) on a
panel of 80 primary invasive breast tumors. Quantitative real-time PCR (qRT-PCR) and western blot analysis were
performed to verify the expression levels of the candidate biomarkers. Patient disease-specific survival (DSS) and
recurrence-free survival (RFS) were evaluated using the Kaplan-Meier method. The prognostic biomarkers were
identified by univariate analysis with a log-rank test and by multivariate analysis with Cox proportional hazards
regression models.
Results: The GGH and FAAH protein levels were significantly up-regulated in invasive breast cancer tumors
compared with adjacent non-cancerous tissues. Furthermore, the protein levels of GGH and FAAH were significantly
correlated in tumor tissues. Tumoral GGH protein expression was significantly correlated with shorter DSS and RFS.
Furthermore, the protein expression of GGH was positively correlated with undifferentiated tumors (BRE grade III)
and ER/PR expressing tumors. Multivariate regression analysis showed that only GGH protein expression
independently predicts DSS. No such correlations were found for FAAH, PIR and TAF5L protein expression.
However, elevated protein levels of FAAH were positively associated with high number of lymph node involvement
and upregulated levels of PIR were positively related with lymph node metastasis. The TAF5L was pronouncedly
down-regulated in primary invasive breast cancer tissues compared to matched adjacent non-cancerous tissues.
Conclusion: These data show for the first time that cytoplasmic GGH might play a relevant role in the
development and progression of invasive breast cancer, warranting further investigations. Our findings suggest that
GGH serve as a potential biomarker of unfavorable clinical outcomes over short-term follow-up in breast cancer.
The GGH may be a very attractive targeted therapy for selected patients.
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Breast cancer remains a deadly disease and still ranks
second among cancer death in women. Clinically, breast
cancer represents a heterogeneous and complex disease
characterized by uncontrolled cell proliferation and divi-
sion. The heterogeneity of breast tumors is mirrored in
the identification of at least five molecular subtypes in-
cluding basal-like, luminal A, luminal B, HER2-enriched
and normal-like, which are believed to originate from
different cell types and follow different progression path-
ways [1,2]. Several well-established markers including
axillary lymph node status, tumour size, histological
grade, hormone receptor status, and HER2/neu status
are used for prognostic evaluation, diagnosis and treat-
ment decisions. However, it should be noted that several
novel prognostic markers that fully capture the hetero-
geneity of breast cancer and do accurately predict it is yet
to be identified. Therefore, the identification and clinical
implementation of tumour- associated biomarkers for
breast cancer to avoid unpleasant side effects with conse-
quent healthcare costs, remains a big challenge.
Previously, we performed gene expression analysis in
46 axillary lymph node negative tumors [3]. Our analysis
showed a critical role of 51 genes whose persistently
deregulated mRNA levels were significantly associated
with unfavorable clinical outcome. The identified 51-
gene signature was then evaluated on independent exter-
nal data sets predicating distance metastasis in breast
cancer patients with lymph-node-negative tumours [4].
Of special interest, four genes (GGH, FAAH, PIR and
TAF5L) among the identified 51-gene signature were sig-
nificantly found to be associated with distant metastases
[3,4]. In the present study, the candidate biomarkers
GGH, FAAH, PIR and TAF5L were therefore selected for
further analysis. In addition, several publications report
their involvement in various cancer forms [5-8].
The GGH catalyzes the hydrolysis of (anti)folylpoly-
gamma-glutamates by the removal of gamma-linked poly-
glutamates [9]. Intracellular folates are essential as cofactors
in DNA synthesis and repair, and also required for normal
cellular proliferation and replication. Anti- folates are es-
sential as inhibitors of folate-dependent enzymes [10]. They
are commonly used in the treatment of various cancer
forms, including acute lymphoblastic leukemia, lymphoma,
breast cancer, and head and neck cancer [11,12]. Increased
expression levels of GGH were reported to be associated
with resistance to methotrexate in human sarcoma cell
lines [13]. In addition, glutamate was reported to stimulate
tumor proliferation and survival via activation of the MAPK
and PI3K/Akt pathways in glioma cases [14,15]. The FAAH
belongs to a diverse class of enzymes referred to as the ami-
dase signature (AS) family [16]. It regulates the degradation
of the main endocannabinoid, anandamide related fatty
acid amides [17]. The cannabinoids are bioactive lipidsmediators that suggested having a protective effect against
tumor growth [18]. The up-regulation of FAAH has been
reported to stimulate invasion of prostate carcinoma cells
and potentially play a role in prostate tumorigenesis [6].
The PIR is a member of the cupin superfamily [19]. It is a
transcriptional regulator that acts as an interactor of nu-
clear factor I/CCAAT box transcription factor [19]. PIR has
also been reported to interact with the proto-oncoprotein
Bcl-3, which modulates the activity of NF-κB/Rel transcrip-
tion factors [20,21]. The TAF5L protein is a component
of the PCAF histone acetylase complex which efficiently
acetylating histones in a nucleosomal context [22]. The
PCAF histone acetylase complex plays a role in the regula-
tion of transcription, cell cycle progression, differentiation
and as a tumor suppressor [23].
Taken together, we hypothesized that the candidate
biomarkers would allow discriminating tumours accord-
ing to their aggressiveness. To address this hypothesis,
we examined the relationship between GGH, FAAH, PIR
and TAF5L and clinicopathological characteristics, in
addition to survival outcomes using a cohort of 80 inva-
sive breast cancer tumors.
Methods
Tumor specimens
The current study was done in accordance with the guide-
lines of the Declaration of Helsinki and approved by the
Medical Faculty Research Ethics Committee (Gothenburg,
Sweden). Eighty formalin-fixed, paraffin-embedded tissues
(FFPE) and fresh-frozen primary invasive breast tissues
were obtained from the Departments of Pathology and
Oncology at Sahlgrenska University Hospital. The clinico-
pathological characteristics of the tumors are presented in
Table 1. The patients’ follow-up time extended from
1–17 years, and the median survival at the last follow-up
was 8 years. Therefore, the primary invasive breast tissues
were stratified according to disease-specific survival (DSS)
with 8-year censoring. Representative imprints from the
fresh-frozen tumors were evaluated for the ratio of can-
cer/histologically normal cells. The imprints were air dried
and stained with May-Günwald-Giemsa (Chemicon,
Temecula, CA, USA). The presence of the least 50% can-
cer cells was required for the specimen to be included in
this study.
Immunohistochemistry (IHC)
Immunohistochemical staining for GGH, FAAH, PIR
and TAF5L was carried out in 4-μm tissue sections pre-
pared from formalin-fixed, paraffin-embedded tissue
blocks (FFPE).
The FFPE slides were deparaffinised, rehydrated and
processed with the Dako EnVision™ FLEX antigen re-
trieval EDTA buffer pH 9 using DAKO PT Link module
(PT Link, Dakocytomation, Denmark) according to the
Table 1 Clinicopathological characteristics of 80 invasive
breast cancer patients




No. of patients (%)
Mean age (years) 55 (27–73) 51 (33–72)
Histologic type
Invasive ductal 33 (82.5) 31 (77.5)
Invasive lobular 3 (7.5) 7 (17.5)
Invasive ductal +
lobular
0 (0) 1 (2.5)
Other 3 (7.5) 1 (2.5)
Not available 1 (2.5) 0 (0)
Pathologic tumor
size (mm)
pT1 (0–20) 8 (20) 8 (20)
pT2 (>20-50) 27 (67.5) 29 (72.5)
pT3 (>50) 5 (12.5) 3 (7.5)
BRE grade
I-II 21 (100) 20 (100)
III 19 (100) 20 (100)
No. of axillary
lymph nodes
0 14 (35) 14 (35)
1-3 12 (30) 12 (30)
≥4 14 (35) 14 (35)
ER/PR receptor
Negative 19 (47.5) 20 (50)
Positive 20 (50) 20 (50)
Not available 1 (2.5) 0 (0)
HER2 status
Positive 15 (37.5) 11 (27.5)
Negative 21 (52.5) 20 (50)
Not available 4 (10) 9 (22.5)
Surgery
Lumpectomy 15 (37.5) 15 (37.5)
Mastectomy 25 (62.5) 25 (62.5)
Radiotherapy
No 19 (86) 19 (47.5)
Yes 11 (20) 20 (50)
Not available 2 (9) 1 (2.5)
Chemotherapy
No 12 (36.5) 16 (41)
Yes 17 (51.5) 23 (59)
Not available 4 (12) 0 (0)
Endocrine therapy
No 15 (45.5) 20 (51)
Yes 13 (39.5) 18 (46)
Not available 5 (15) 1 (3)
Recurrence
Table 1 Clinicopathological characteristics of 80 invasive
breast cancer patients (Continued)
No 15 (45) 10 (25)
Yes 3 (10) 15 (37.5)
Not available 15 (45) 15 (37.5)
BRE, Bloom, Richardson, Elston/Ellis; HR, hazard ratio; CI, confidence interval;
ER/PR, Estrogen/Progesterone receptor. All parameters were coded as 0
(negative) and 1 (positive) except as noted. Histologic type was coded as 1
(ductal), 2 (lobular ductal), 3 (ductal and lobular) and 4 (other).
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performed using DAKO stainer (DAKO Auotstainer
plus, Dakocytomation, Denmark) following the manu-
facturer’s instructions. The antibodies employed were
rabbit anti-GGH (HPA025226, 1:200; Sigma-Aldrich,
Stockholm, Sweden), rabbit anti-FAAH (HPA007425,
1:100; Sigma-Aldrich), rabbit anti-PIR (HPA000697, 1:300;
Sigma-Aldrich) and rabbit anti-TAF5L (H00027097-B01,
1:50; Novus Biologicals, Stockholm, Sweden). The scoring
of IHC stains in each specimen was evaluated by two
pathologists; one of them (AK) reviewed all samples while
the other analyzed a portion of the samples. Both patholo-
gists were unaware of the survival outcomes and other
clinic-pathological data. The immunoreactivity for GGH,
FAAH, PIR and TAF5L was separately analyzed in the ma-
lignant epithelial cell compartments of the tumor (cance-
rous cells) and the adjacent histologically normal epithelial
cells (non-cancerous cells) from the same specimens. The
immunoreactivity was defined as negative, indicating no
staining is observed. The cytoplasmic, membranous or nu-
clear staining in less than 10% of the cells was also consi-
dered as negative. In order to distinguish positive from
negative staining as for ER and Her2/neu staining, the
immunoreactivity was considered as positive, indicating
weak, moderate or strong staining in more than 10% of the
invasive tumor cells [24,25]. The cytoplasmic, membranous
and nuclear staining was classified as either negative or
positive for subsequent statistical analyses.
Fluorescence in situ hybridization (FISH)
To assess HER2/neu gene status in the 67/80 availa-
ble fresh-frozen tumor samples, fluorescence in situ
hybridization was performed. A bacterial artificial chromo-
some (BAC) clone covering the HER2/neu locus (RP11-
94 L15) was purchased from BACPAC Resource Center
(Oakland, CA, USA, http://bacpac.chori.org/) and used as
a FISH probe. FISH was performed on tumor touch-prints
prepared from fresh-frozen tumors as described previously
[26]. The analysis was performed using a Leica DMRA2
fluorescence microscope (Leica, Stockholm, Sweden)
equipped with an ORCA Hamamatsu charged-couple
devices camera (Hamamatsu Corporation, Stockholm,
Sweden). Scoring of HER2/neu hybridization signals was
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ber of signals in at least 100 nuclei. Specimens were scored
as either positive (1) when HER2/neu gene amplifications
were detected in more than 10% of the analyzed cells or
negative (0) in all other cases
Quantitative real-time PCR (qRT-PCR)
QRT-PCR was performed on a cohort of 62/80 tumors
which were also used in the IHC analyses. Total RNA was
isolated from frozen tumor tissues using TRIzol reagent
(Life Technologies, Stockholm, Sweden) and the Qiagen
RNeasy mini kit (Qiagen, Stockholm, Sweden) according to
the manufacturer’s instructions. DNase treated (Ambion,
Texas, US) total RNA was converted subsequently to
cDNA using random hexamers and Superscript III (Life
Technologies) according to standard procedures. The can-
didate genes were analyzed using TaqMan Gene expression
assays; GGH (Hs00914163_m1), FAAH (Hs01038660_m1),
PIR (Hs01125822_m1),TAF5L (Hs01039207_m1) from Life
Technologies. All assays were carried out in duplicate in a
10 μl reaction volume including: 2 μl of cDNA template, 2x
TaqMan Universal PCR Master Mix (ABI, Foster City,
USA), and 1x FAM labeled gene-specific assay. All qRT-
PCR reactions were performed in 384-well plates using the
ABI PRISM 7900HT Sequence Detection System (ABI,
Foster City, USA) with an initiation step at 95°C for 10 min-
utes, followed by 40 cycles at 95°C for 15 seconds and at
60°C for 1 minute. For each assay, a template dilution
standard curve (5-fold range) was recorded. The HPRT1
gene (Hs02800695_m1) was initially selected as an en-
dogenous control based on its constitutive expression using
the Illumina HumanHT-12 platform. Moreover, it exhibited
low variance in mRNA expression between samples (data
not shown). Relative gene expression levels were calculated
with the relative standard curve method using CT values of
the analyzed genes normalized with HPRT1. Genomic
DNA and no-template samples were included as controls.
Dissociation curves were performed and the samples were
run on gels for GGH, FAAH, PIR, TAF5L and HPRT1 to
further verify a single band of the correct size.
Western blotting
Western blotting as previously described [27], was per-
formed on 7 selected cases of invasive breast tumors which
were also used in the IHC and qRT-PCR analyses. The
rabbit polyclonal antibodies employed were anti-GGH
(HPA025226, 1:200; Sigma-Aldrich) and anti-GAPDH
(sc-25778, 1:500; Santa Cruz Biotechnology). Imaging ana-
lysis was performed using Alpha Ease FC software.
Statistical analysis
Statistical analyses were performed using SPSS version 20
software. The probabilities of DSS and RFS were estimated
by the Kaplan–Meier method, and survival differences weredetermined by the log-rank test. Survival data were evalu-
ated using univariate and multivariate Cox regression ana-
lyses. Cox regression multivariate analysis was performed
to identify the independent prognostic factors for predic-
ting DSS. Where appropriate, the chi-square test or t-test
was applied to evaluate association. McNemar’s and Exact
McNemar’s tests for paired data were used to compare the
expression levels of each candidate biomarker in tumor tis-
sues with their matched adjacent non-cancerous tissues.
Results
Clinicopathological characteristics
Due to loss of biopsy cores, insufficient tumor cells present
in the cores or affluence of necrotic tissue, 72 FFPE speci-
mens out of the collected 80 FFPE specimens were evalu-
ated for GGH, FAAH, PIR and TAF5L immunostaining.
The ages of the patients ranged from 27–73 years (median
age: 53 years). The tumor sizes ranged from 1.3–7.3 cm
(median: 3 cm). Most of the tumors (64/80) were histolo-
gically diagnosed as invasive ductal carcinoma, whereas
others included invasive lobular carcinoma (10 cases), both
type of carcinomas (1 case), other (4 cases), and not avail-
able (1 case). For all cases, tumor differentiation was
assessed. Of these, 41 tumors were well-to-moderately dif-
ferentiated (BRE grade I and II), while 39 tumors were
poorly differentiated (BRE grade III). The cohort consisted
of long-term survivors (46%, ≥8 years) and short-term sur-
vivors (54%, <8) following diagnosis. Patients were fol-
lowed up until March 2011 and during this follow-up
period, 1 patient had local recurrence, whereas 17 patients
developed distant metastasis (Table 1).
GGH, FAAH, PIR and TAF5L protein levels in invasive
breast cancer and non-cancerous tissues
Breast ductal and lobular epithelial cells exhibited weak
to moderate GGH and FAAH staining in the cell cyto-
plasm. The TAF5L was expressed in the cell nucleus
whereas PIR protein was mainly observed in the cyto-
plasm (92%) or was expressed in both the cytoplasm and
cell membrane (8%; Figure 1A and Figure 2). As seen in
Table 2, positive expression of GGH was detected in
19% non-cancerous breast tissues, while the remaining
tissues had negative staining for GGH. Among the
tumor tissues 75% (54/72) of the cases showed positive
expression of GGH (χ2 = 17.9, P < 0.001). Four percent of
the FAAH protein expression was positive in non-
cancerous breast tissues whereas 89% of the breast can-
cer tissues expressed FAAH (χ2 = 19.3, P < 0.001). The
frequency and levels of PIR expression was similar bet-
ween non-cancerous and invasive breast cancer tissues.
Eighty-six percent of non-cancerous breast tissues and
85% of the breast cancer tissues were positive for PIR
expression. The TAF5L protein levels were elevated in
the cell nucleus of the non-cancerous cells compared to
Figure 1 Detection of GGH protein levels in invasive breast cancer tissues. (A) Immunohistochemical staining of GGH protein expression in
primary invasive breast tumors. (B) Western blot analysis of GGH protein levels in 7 primary invasive breast cancer tumors. Note: P = GGH-expressing
tumor tissues; N = GGH-negative tumor tissues as assessed by immunohistochemistry; IHC = Immunohistochemistry. GAPDH assesses equal loading.
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(χ2 = 28.2, P < 0.001; Table 2). The expression of GGH
was further confirmed by western blot analysis in 7 rep-
resentative patients whose fresh-frozen tissues were
available and a tight correlation between the results of
the immunohistochemistry and the western blot analysis
were observed. Interestingly, two closely spaced bands
corresponding to GGH protein expression were detected
at 33- and 37-kD (Figure 1B).
Correlation of GGH, FAAH, PIR and TAF5L protein levels
to clinicopathological characteristics of invasive breast
cancer
As seen in Table 3, GGH protein expression was signifi-
cantly associated with high histological tumor grade (BRE
grade III, P < 0.001), and ER/PR receptors (P = 0.01). There
was no difference in GGH expression between different
pathologic tumor size, histologic tumor type, axillary
lymph node status, HER2/neu status or age in the cohort’s
tissues. A significant association between FAAH expres-
sion and patients with more than 4 axillary lymph node
metastases (P = 0.023) was observed (Table 3). The expres-
sion of PIR was positively correlated with lymph node
metastasis (P = 0.034). The TAF5L protein levels were al-
most attained statistical significant correlation with the
low histological tumor grade (BRE grade I/II; P = 0.06),whereas no associations with other clinicopathological
parameters were detected (Table 3).
The association among the levels of GGH, FAAH, PIR
and TAF5L proteins was also examined. In tumor tissue
samples, seventy-one percent of the tumors had positive ex-
pression of GGH and FAAH simultaneously. Seven percent
of the tumors had negative expression of GGH and FAAH
at the same time. A significant correlation between GGH
and FAAH was detected (r = 0.31, P = 0.02; Table 3). On
the other hand, no association was observed between the
expression of PIR and/ or TAF5L and the expressions of
the other proteins (Table 3). In non-cancerous tissues, no
significant correlation was detected among the expression
levels of GGH, FAAH, PIR and TAF5L (data not shown).
Cytoplasmic expression of GGH is associated with
unfavorable clinical outcomes
The effect of GGH, FAAH, PIR and TAF5L protein ex-
pression on patients DSS was conducted by Kaplan-Meier
analysis. An inverse correlation between the expression of
GGH and 5 year DSS (P = 0.024; data not shown) and
8 year DSS (P = 0.037; Figure 3) was observed. Eight-year
DSS rate was 39% among patients with GGH expressing
tumors compared to 68% among patients whose tumors
were GGH-negative. Furthermore, the univariate Cox pro-
portional hazards regression analysis revealed that GGH
Figure 2 Immunohistochemical detection of FAAH, PIR and
TAF5L protein levels in primary invasive breast tumors (A-C).
Table 2 GGH, FAAH, PIR and TAF5L expression in paired
cancer and non-cancer tissues
Cancer Non-cancer
N (%) N (%) P-value*
GGH
Positive 54 (75) 14 (19)
Negative 18 (25) 58 (81 <0.001
FAAH
Positive 64 (89) 3 (4)
Negative 8 (11) 69 (96) <0.001
PIR
Positive 61 (85) 62 (86)
Negative 11 (15) 10 (14 1
TAF5L
Positive 32 (44) 67 (93)
Negative 40 (66) 5 (7) <0.001
N = number of patients.
* MCNemar test.
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fold higher risk of death (95% CI: 1.0-6.8, P = 0.04; Table 4).
Moreover, the recurrence-free survival (RFS) of invasive
breast cancer patients was also analyzed. Importantly, an
adverse association between the expression of GGH and
RFS was observed (P = 0.009; Table 3). Also, patients with
tumors expressing GGH had a 35.5 fold higher risk of re-
currence (95% CI: 0.43–2932, P = 0.009). As shown inFigure 4, the 8-year RFS rate was 100% in GGH- negative
tumors, while it dramatically decreased to 10% in GGH
expressing tumors.
Subsequently, all clinicopathological characteristics in-
cluding age, ER/PR status, HER2/neu status, histologic
tumor type, pathologic tumor size, histologic tumor
grade and axillary lymph node status were enrolled in
multivariate survival analysis, which showed that the ex-
pression of GGH protein still retained its significance as
an independent prognostic factor for unfavorable DSS
(95% CI: 1.3–10.3, P = 0.02; Table 5). The differences in
DSS and RFS based on the protein levels of FAAH, PIR
and TAF5L was also examined. As seen in Table 4, no
significant association was detected and the expression
levels of FAAH, PIR and TAF5L were not significant in
univariate analysis.
To further confirm the results of IHC, we assessed GGH,
FAAH, PIR and TAF5L mRNA expression levels by qRT-
PCR. The GGH mRNA expression was positively corre-
lated with protein levels evaluated by IHC (t-test, P = 0.023;
Figure 5). The overall concordance between qRT-PCR and
IHC data for GGH was 92% (57/62). The five discordant
tumor samples had high GGH protein levels despite
low GGH mRNA levels. In contrast, poor agreement
between qRT-PCR and IHC data for FAAH, PIR and
TAF5L were observed (t-test, P= 0.70, P= 0.51 and P= 0.38
respectively; Figure 5).
Discussion
The identification of novel biomarkers that can help to
define individual risk signatures in breast cancer patients
are of great clinical value, as they might allow individua-
lized treatments. Previously, we and others have identi-
fied candidate molecular gene signatures associated with
Table 3 The association of GGH, FAAH, PIR and TAF5L to the clinicopathological characteristics in addition to clinical
outcomes
Characteristics FAAH PIR TAF5L GGH
Negative Positive Negative Positive Negative Positive Negative Positive
8 (100) 64 (100) 11 (100) 61 (100) 40 (100) 32 (100) 18 (100) 56 (100)
Survival ≥8 yrs 4 (12) 29 (88) 4 (12) 29 (88) 18 (55) 15 (45) 11 (36) 22 (64)
Survival <8 yrs 4 (10) 35 (90) 7 (18) 32 (82) 22 (57) 17 (43) 5 (16) 34 (84)
P = 0.55 P = 0.53 P = 1 P = 0.037
Recurrence
No 3 (12) 22 (88) 2 (8) 23 (92) 16 (64) 9 (36) 9 (36) 16 (64)
Yes 0 (0) 18 (100) 2 (11) 16 (89) 7 (39) 11 (61) 0 (0) 18 (100)
P = 0.29 P = 0.87 P = 0.12 P = 0.009
Age
27-59 2 (9) 20 (91) 3 (14) 19.(86) 12 (55) 10 (45) 6 (27) 16 (73)
≥60 16 (73) 44 (88) 8 (16) 42 (84) 28 (56) 22 (44) 12 (24) 38 (76)
P = 0.54 P = 1 P = 1 P = 0.78
BRE grade
I-II 5 (14) 31 (86) 4 (11) 32 (89) 16 (44) 20 (66) 15 (42) 21 (58)
III 3 (8) 33 (92) 7 (19) 29 ( 81) 24 (67) 12 (33) 3 (8) 33 (92)
P = 0.71 P = 0.51 P = 0.06 P <0.001
Axillary lymph node status
Negative 2 (8) 22 (92) 7 (29) 17 (71) 14 (58) 10 (42) 5 (21) 19 (79)
Positive 6 (13) 42 (87) 4 (8) 44 (92) 26 (54) 22 (46) 13 (27) 35 (73)
P = 0.71 P = 0.034 P = 0.81 P = 0.88
No. of axillary lymph nodes
1-3 0 (0) 23 (100) 1 (4) 22 (96) 13 (43) 17 (57) 6 (26) 17 (74)
≥4 6 (24) 19 (76) 3 (12) 22 (88) 10 (56) 8 (44) 7 (28) 18 (72)
P = 0.023 P = 0.6 P = 0.56 P = 0.63
ER/PR status
Negative 5 (15) 29 (85) 4 (12) 30 (88) 19 (56) 15 (44) 10 (41) 27 (59)
Positive 3 (8) 35 (92) 7 (18) 31.(82) 21 (55) 17 (45) 4 (10) 34 (90)
P = 0.46 P = 0.52 P = 0.26 P = 0.01
HER2/neu status
Negative 5 (14) 32 (86) 7 (19) 30 (81) 20 (54) 17 (46) 10 (71) 4 (29)
Positive 1 (5) 21 (95) 2 (9) 20 (91) 13 (59) 9 (41) 27 (60) 18 (40)
P = 0.4 P = 0.46 P = 0.79 P = 0.53
FAAH
Negative 2 (18) 9 (82) 4 (50) 4 (50) 5 (28) 13 (72)
Positive 6 (10) 55 (90) 36 (56) 28 (44) 3 (6) 51 (94)
- P = 0.6 P = 1 P = 0.02
PIR
Negative 2 (25) 6 (75) 7 (64) 4 (36) 2 (11) 16 (89)
Positive 9 (14) 55 (86) 33 (54) 28 (46) 9 (17) 45 (83)
P = 0.6 - P = 0.74 P = 0.72
TAF5L
Negative 4 (10) 36 (90) 3 (27) 8 (73) 5 (28) 13 (72)
Positive 4 (13) 28 (87) 13 (21) 48 (79) 11 (20) 43 (80)
P = 1 P = 0.7 - P = 0.53
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Table 3 The association of GGH, FAAH, PIR and TAF5L to the clinicopathological characteristics in addition to clinical
outcomes (Continued)
GGH
Negative 5 (63) 3 (37) 2 (18) 9 (82) 8 (44) 10 (66)
Positive 13 (20) 51 (80) 16 (26) 45 (74) 32 (59) 22 (41)
P = 0.02 P = 0.72 P = 0.53 -
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[3,4]. In the present study, we investigated the clinical sig-
nificance of the candidate biomarkers GGH FAAH, PIR
and TAF5L in predicting breast cancer progression.
In the present study, we found that the elevated cyto-
plasmic protein levels of GGH were mainly localized to
the tumor cells in comparison to adjacent non-cancerous
cells. In urothelial carcinoma of the bladder, elevated level
of GGH was also detected in cancerous cells in compari-
son with non-cancerous cells [5]. In addition, tumoral
GGH protein levels were significantly up-regulated in high
histological grade tumors in comparison with low histo-
logical grade tumors. Taken together, these finding suggest
that the expression of GGH is associated with invasiveness




Figure 3 Kaplan-Meier depicting disease-specific survival in breast ca
TAF5L (A-D). Dashed line represents patients whose tumors expressed GG
whose tumors did not express GGH (A-D). The p-values for the difference bprogresses. However, detected GGH protein in the non-
cancerous tissues may represents the normal function of
GGH in maintaining tissue homeostasis of (anti)folate,
glutamates or may predict progression of premalignant
lesions [28]. High levels of tumoral GGH were also
observed to be significantly associated with ER/PR recep-
tors. Eight-year survival of patients with low expression of
GGH was significantly better than those with a higher ex-
pression. In addition, the multivariate analysis verified that
GGH is an independent negative factor in predicting pa-
tient DSS as presented by the fact that hazard ratio (HR)
for GGH adjusted for age, histological type, histological
grade, ER/PR status, HER2/neu status, pathologic tumor
size, and axillary lymph node status remained significant.




ncer according to expression patterns of GGH, FAAH, PIR and
H (A), FAAH (B), PIR (C) and TAF5L (D). Solid line represents patients
etween the curves were calculated using log-rank test.
Table 4 Univariate Cox proportional hazard analysis for
disease-specific survival




GGH 0.98 0.48 4.20 0.04 2.67 1.00 6.80
FAAH −0.04 0.40 0.02 0.91 0.96 0.44 2.08
PIR −0.29 0.42 0.49 0.48 0.75 0.33 1.70
TAF5L −0.10 0.32 0.09 0.76 0.91 0.48 1.71
β: Regression coefficient; SE: standard error of β; HR: hazard ratio; and CI:
confidence interval.
Table 5 Multivariate Cox proportional hazard analysis for
disease-specific survival




AGE −0.10 0.35 0.03 0.85 0.94 0.47 1.87
GGH 1.20 0.53 5.81 0.02 3.62 1.27 10.3
Histological type −0.60 0.39 3.09 0.07 0.51 0.24 1.08
BRE grade −0.05 0.18 0.07 0.78 0.95 0.67 1.34
ER/PR status 0.14 0.35 0.18 0.67 1.12 0.59 2.29
HER2/neu status −0.40 0.38 0.95 0.33 0.69 0.32 1.46
Pathological size −0.01 0.01 0.23 0.63 0.10 0.97 1.02
Axillary lymph nodes 0.05 0.36 0.02 0.87 1.06 0.52 2.16
β: Regression coefficient; SE: standard error of β; HR: hazard ratio; and CI:
confidence interval. BRE: Bloom, Richardson, Elston/ Ellis; ER/PR:
Estrogen/Progesterone receptor.
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http://www.biomedcentral.com/1471-2407/13/47promoting carcinogenesis. Furthermore, the elevated
levels of GGH was found to be correlated with shorter
RFS with more than 35 fold increased risk, suggesting that
GGH expression may predict the recurrence behavior of
breast cancer. Notably, the association between GGH ex-
pression and different cancer forms has been previously
reported. The elevated levels of GGH were reported to be
correlated with poor clinical outcome in pulmonary neu-
roendocrine tumors [29]. Elevated plasma level of GGH
was observed in patients with metastatic breast cancer in
comparison to control subjects and to patients with can-
cer in remission [30]. High GGH expression level was also
detected in hepatoma cells compared with rat hepatocytes
[31]. Furthermore, GGH expression was found to act as a
prognostic biomarker for acute leukemia in response to
methotrexate therapy [32]. Consistent with these findings,
our data further suggest that the dysfunction of GGH may
play an important role in breast cancer progression andFigure 4 Kaplan–Meier illustrating the recurrence-free survival of bre
line represents patients whose tumors expressed GGH and solid line repres
between the curves were calculated using log-rank test.GGH may be an amenable therapeutic target in breast
cancer.
In tumor tissues, the mRNA expression of GGH was
increased specifically in patients with short-term survivor.
This increase corresponded to protein accumulation based
on IHC, indicating transcriptional activation. However,
the GGH gene may be also regulated in tumors at post-
transcriptional levels, since the GGH protein in 5 of 62 in-
vasive breast cases was elevated, whereas no increase in
mRNA was observed in these samples by qRT-PCR.
The cytoplasmic expression of FAAH was significantly
up-regulated in invasive breast tumor tissues compared
to the non-cancerous tissues. In addition, the expressionast cancer patients on the basis of GGH expression levels. Dashed





Figure 5 The relationship between GGH, FAAH, PIR and TAF5L
mRNA levels with their corresponding protein levels in breast
cancer patients. The box plots Positive and Negative indicate
corresponding gene expression levels for each protein. The mRNA
expression of GGH was consistent with the IHC findings. There was
no association of FAAH, PIR and TAF5L mRNA levels to their
corresponding protein levels.
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http://www.biomedcentral.com/1471-2407/13/47levels of FAAH were significantly increased in patients
with higher number of axillary lymph node metastases.
Up-regulation of FAAH indicates down-regulation of
cannabinoids, which play an important role in preven-
ting tumor growth [18]. Taken together, these findings
suggest that elevated level of FAAH may promote breast
cancer tumors invasion and metastasis. Interestingly, a
significant correlation between GGH and FAAH protein
expressions was detected in the tumor tissues, whereas
no association in the non-cancerous tissues was seen,
suggesting that the tumor micro-environmental effects
may regulate the expression of GGH and FAAH simul-
taneously [33]. In addition, GGH accumulation may re-
flect a functional correlation with FAAH expression,
which could play a role in the progression of breast car-
cinoma. In the current study, expression of PIR in tumor
tissues was virtually similar to the non-cancerous tissues.
Previous studies reported that some gene expression pat-
terns in the invasive tissues are comparable to their non-
invasive breast tissues, suggesting that these signatures
may predict progression of early premalignant lesions in
non-cancerous tissues [28,34,35]. The PIR functions as a
transcriptional regulator whose expression is deregulated
in several cancer types. Furthermore, high expression of
PIR was reported to be essential to overcome the senes-
cence barrier [36]. We also examined the clinicalsignificance of PIR protein expression. The higher ex-
pression of PIR was significantly associated with pres-
ence of lymph node metastasis, suggesting that the
expression of PIR is associated with invasiveness and
supports the reported association of PIR expression with
enhanced malignant potential [36,37].
In the present study, the nuclear expression of TAF5L
was significantly down-regulated in invasive breast
tumor tissues compared to the non-cancerous tissues,
which suggests a potential tumor suppressor role in
breast cancer. The expression of TAF5L was elevated in
patients with low histological grade tumors compared to
patients with high histological grade tumors, although
the differences were not significant (P = 0.06). Further-
more, high mRNA expression levels of TAF5L were
detected in 97% of the analyzed tumors, whereas only
56% of the analyzed tumors expressed TAF5L protein.
The reduction of TAF5L protein in the analyzed tissues
may contribute to disease progression.
The discordant results detected between mRNA and
protein expression of FAAH, PIR and TAF5L, could be
due to multiple factors including, tumor heterogeneity,
posttranscriptional regulation, differences in mRNA and
protein turnover rates or poor specificity of the antibody
used for IHC [38,39].
In the cohort of 80 patients, even though the expression
of FAAH, and PIR did not predict DSS and RFS, the ex-
pression of these candidate biomarkers were significantly
associated with other clinicopathological characteristics.
These results need to be further validated by a larger sam-
ple size and additional studies are needed to elucidate the
molecular mechanisms through which GGH, FAAH, PIR
and TAF5L may participate in the development and pro-
gression of breast cancer.
Conclusion
We demonstrate that elevated protein levels of GGH
protein were associated with unfavorable prognosis and
poor outcome in an independent cohort of 80 primary
invasive breast cancer tumors. Paired breast cancer tis-
sues and adjacent non-cancerous tissues have been
found to express GGH differentially, with the cancer tis-
sues displaying significantly higher expression of GGH
protein. In addition, our data suggests that GGH is a
potential independent prognostic factor of DSS when
compared to other widely used prognostic factors. In
addition, we have also demonstrated an association bet-
ween elevated levels of FAAH and PIR and high number
of axillary lymph node involvement and lymph node me-
tastasis, respectively. A significant lower expression of
TAF5L was observed in tumor cells compared with their
adjacent non-cancerous cells. These candidate biomar-
kers may be useful in improved risk stratification in
breast cancer patients. Their prognostic values, however,
Shubbar et al. BMC Cancer 2013, 13:47 Page 11 of 12
http://www.biomedcentral.com/1471-2407/13/47cannot be reliably assessed from the present analyses and
further studies are needed to investigate these possibilities.
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